全文获取类型
收费全文 | 1943篇 |
免费 | 118篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 81篇 |
妇产科学 | 44篇 |
基础医学 | 218篇 |
口腔科学 | 34篇 |
临床医学 | 271篇 |
内科学 | 317篇 |
皮肤病学 | 23篇 |
神经病学 | 277篇 |
特种医学 | 106篇 |
外科学 | 256篇 |
综合类 | 13篇 |
一般理论 | 6篇 |
预防医学 | 121篇 |
眼科学 | 9篇 |
药学 | 105篇 |
中国医学 | 4篇 |
肿瘤学 | 174篇 |
出版年
2023年 | 12篇 |
2022年 | 8篇 |
2021年 | 35篇 |
2020年 | 25篇 |
2019年 | 45篇 |
2018年 | 42篇 |
2017年 | 38篇 |
2016年 | 48篇 |
2015年 | 51篇 |
2014年 | 78篇 |
2013年 | 73篇 |
2012年 | 131篇 |
2011年 | 128篇 |
2010年 | 98篇 |
2009年 | 94篇 |
2008年 | 136篇 |
2007年 | 119篇 |
2006年 | 138篇 |
2005年 | 103篇 |
2004年 | 94篇 |
2003年 | 95篇 |
2002年 | 79篇 |
2001年 | 11篇 |
2000年 | 7篇 |
1999年 | 16篇 |
1998年 | 40篇 |
1997年 | 27篇 |
1996年 | 35篇 |
1995年 | 35篇 |
1994年 | 33篇 |
1993年 | 27篇 |
1992年 | 8篇 |
1991年 | 11篇 |
1990年 | 9篇 |
1989年 | 18篇 |
1988年 | 15篇 |
1987年 | 7篇 |
1986年 | 17篇 |
1985年 | 11篇 |
1984年 | 7篇 |
1983年 | 4篇 |
1982年 | 6篇 |
1981年 | 4篇 |
1980年 | 7篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1957年 | 6篇 |
1956年 | 4篇 |
1955年 | 4篇 |
1954年 | 5篇 |
排序方式: 共有2066条查询结果,搜索用时 15 毫秒
71.
Ivana Verlinden Karin van den Hurk Ruud Clarijs Arjan P. Willig Cecile M.H.A. Stallinga Guido M.J.M. Roemen Joost J. van den Oord Axel zur Hausen Ernst-Jan M. Speel Véronique J.L. Winnepenninckx 《Medicine》2014,93(28)
Treatment of BRAFV600E-mutant melanoma by small molecule inhibitors that target BRAF or MEK kinases is increasingly used in clinical practice and significantly improve patient outcome. However, patients eventually become resistant and therapeutic improvement is required. Molecular diversity within individual tumors (intratumor heterogeneity) and between tumors within a single patient (intrapatient heterogeneity) poses a significant challenge to precision medicine.Using immunohistochemistry, we determined the extent of BRAFV600E intratumor and intrapatient heterogeneity and the influence of morphological heterogeneity in a large series of 171 melanomas of 81 patients.The BRAFV600E mutation rate found in our melanoma series is 44%, with none of 22 (0%) melanoma in situ, 23 of 56 (41%) primary tumors, 28 of 59 (48%) regional metastases, and 24 of 34 (71%) distant metastases harboring the mutation. In general, a diffuse homogeneous immunostaining was seen, even in tumors consisting of more than one cell type, that is, epithelioid, spindle, and/or small cell types. Nevertheless, BRAFV600E-mutant melanomas more often had a purely epithelioid cell population (P = 0.063), that is more evident among distant metastases (P = 0.014). Only two of 75 (3%) mutated specimens (one primary and one metastasis) displayed heterogeneous BRAFV600E expression. The primary tumor was also morphologically heterogeneous and exclusively displayed BRAFV600E in the epithelioid component, confirming an association between BRAFV600E and epithelioid cells. Twenty-eight of 30 patients (93%) had concordant BRAF mutation status between their tumors.Taken together, BRAFV600E intratumor and intrapatient heterogeneity in melanoma is diminutive, nevertheless, the identified exceptions will have important implications for the clinical management of this disease. 相似文献
72.
Barbara J. van den Hoofdakker Pieter J. Hoekstra Lianne van der Veen-Mulders Sjoerd Sytema Paul M. G. Emmelkamp Ruud B. Minderaa Maaike H. Nauta 《European child & adolescent psychiatry》2014,23(11):1071-1079
This study aims to explore the influence of paternal variables on outcome of behavioral parent training (BPT) in children with attention-deficit/hyperactivity disorder (ADHD). 83 referred, school-aged children with ADHD were randomly assigned to BPT plus ongoing routine clinical care (RCC) or RCC alone. Treatment outcome was based on parent-reported ADHD symptoms and behavioral problems. Moderator variables included paternal ADHD symptoms, depressive symptoms, and parenting self-efficacy. We conducted repeated measures analyses of variance (ANOVA) for all variables, and then analyzed the direction of interaction effects by repeated measures ANOVA in high and low scoring subgroups. Paternal ADHD symptoms and parenting self-efficacy played a moderating role in decreasing behavioral problems, but not in decreasing ADHD symptoms. Paternal depressive symptoms did not moderate either treatment outcome. BPT is most beneficial in reducing children’s behavioral problems when their fathers have high levels of ADHD symptoms or high-parenting self-efficacy. 相似文献
73.
Michiel F Schreuder Ruud R G Bueters Karel Allegaert 《Pediatric nephrology (Berlin, Germany)》2014,29(11):2083-2091
The kidney plays a central role in the clearance of drugs. However, renal drug handling entails more than glomerular filtration and includes tubular excretion and reabsorption, and intracellular metabolization by cellular enzyme systems, such as the Cytochrome P450 isoenzymes. All these processes show maturation from birth onwards, which is one of the reasons why drug dosing in children is not simply similar to dosing in small adults. As kidney development normally finishes around the 36th week of gestation, being born prematurely will result in even more immature renal drug handling. Environmental effects, such as extra-uterine growth restriction, sepsis, asphyxia, or drug treatments like caffeine, aminoglycosides, or non-steroidal anti-inflammatory drugs, may further hamper drug handling in the kidney. Dosing in preterm neonates is therefore dependent on many factors that need to be taken into account. Drug treatment may significantly hamper postnatal kidney development in preterm neonates, just like renal immaturity has an impact on drug handling. The restricted kidney development results in a lower number of nephrons that may have several long-term sequelae, such as hypertension, albuminuria, and renal failure. This review focuses on the interplay between drugs and the kidney in premature neonates. 相似文献
74.
75.
76.
77.
78.
Nicole L.W. Van Hal Guus A.M.S. Van Dongen Ellen M.C. Rood-Knippels Paul Van Der Valk Gordon B. Snow Ruud H. Brakenhoff 《International journal of cancer. Journal international du cancer》1996,68(4):520-527
At present, tumor-targeting with monoclonal antibodies (MAbs) is among the most promising novel adjuvant-therapy modalities for the treatment of patients with minimal residual disease of head-and-neck squamous-cell carcinoma (HNSCC). For this purpose we developed MAb U36, recognizing a 200-kDa antigen expressed on the outer cell surface of squamous-cell carcinomas and their normal counterparts. Clinical radioimmunoscintigraphy (RIS) and biodistribution studies have shown that the MAb-U36-defined antigen is a suitable target molecule for antibody-based therapy of head-and-neck cancer. In the present study we further characterized the antigen by cDNA cloning. The cDNA was isolated by expression cloning in COS-7 cells. Sequence analysis and database searching revealed that the MAb-U36-defined antigen is identical to the squamous-cell-specific CD44 splice variant epican. The epitope recognized by MAb U36 was mapped by screening overlapping synthetic peptides of the epican-specific region encoded by exon 7–11 (v3–v7), and appeared to be located in the v6 domain. The applicability of MAb U36 for targeting human tumors of various origin expressing the CD44v6 domain is discussed. © 1996 Wiley-Liss, Inc. 相似文献
79.
Sixty-two hereditary tyrosinaemia type I (HT1) patients of various ethnic origins were classified clinically into acute, chronic, or intermediate phenotypes and screened for the 14 published causal mutations in the fumarylacetoacetase (FAH) gene. Restriction analysis of PCR amplified genomic DNA identified 74% of the mutated alleles. IVS12+5G→A, predominant in the French Canadian HT1 patients, was the most common mutation found in 32 alleles in patients from Europe, Pakistan, Turkey, and the United States. IVS6-1G→T, encountered in 14 alleles, was common in Central and Western Europe. There was an apparent “Scandinavian” 1009G→A combined splice and missense mutation (12 alleles), a “Pakistani” 192G→T splice mutation (11 alleles), a “Turkish” D233V mutation (6 alleles), and a “Finnish” or northern European W262X mutation (7 alleles). The remaining mutations were rare. Some of the mutations seem to predispose for acute and other for more chronic forms of HT1, but in our material no clearcut genotype phenotype correlation could be established. © 1996 Wiley-Liss, Inc. 相似文献
80.
Diede L. Loopik Renée M. Ebisch Joanna IntHout Willem J. Melchers Leon F. Massuger Ruud L. Bekkers Albert G. Siebers 《International journal of cancer. Journal international du cancer》2020,147(3):897-900
Women with cervical intraepithelial neoplasia grade 3 (CIN3) have a long-lasting increased risk for noncervical high-risk human papillomavirus (hrHPV)-related (pre)malignancies. The aim of our study was to estimate this risk in women with recurrent CIN3 compared to women without a history of CIN3 and women with a single episode of CIN3. Women with a CIN3 diagnosis between 1990 and 2010 were obtained from the Dutch Pathology Registry (PALGA) and matched with a control group of women without CIN3. Analysis has been conducted in a subset of women with recurrent CIN3, defined as reoccurrence minimally 2 years post-treatment. Cases of noncervical hrHPV-related (pre)malignancies of the anus, vulva, vagina and oropharynx were identified until 2015 and incidence rate ratios (IRRs) were estimated. Then, 1,797 women with recurrent CIN3 were included with a median age of 34 years (range 18–76) and 31,594 person-years of follow-up. Women with recurrent CIN3 had an increased risk of developing noncervical hrHPV-related (pre)malignancies compared to women without CIN3 with an IRR of 25.96 (95%CI 6.32–106.58). The IRR was 2.48 (95% CI 1.87–3.30) compared to women with a single episode of CIN3. Studies on posttreatment follow-up and prophylactic hrHPV vaccination are warranted. 相似文献